Gil, Kellen http://orcid.org/0000-0001-8823-2620
Abbasi, Saqib
Mehta, Kathan
McClune, Brian
Sborov, Douglas
Ahmed, Nausheen
Abdallah, Al-Ola
Ganguly, Siddhartha
McGuirk, Joseph
Shune, Leyla
Mohyuddin, Ghulam Rehman
Article History
Received: 11 November 2021
Accepted: 24 February 2022
First Online: 11 May 2022
Declarations
:
: None of authors have any conflicts of interest to declare other than the following. DS: consulting for Janssen, SkylinDx, GlaxoSmithKline, Legend Biotech, Amgen and Celgene. SG: Daiichi Sankyo: Research Funding; Seattle Genetics: Speakers Bureau; Kite Pharma: Honoraria, Other: Advisory Board; Janssen: Honoraria. JM: Kite Pharmaceuticals: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Bellicum Pharmaceuticals: Research Funding; Astellas: Research Funding; Juno Therapeutics: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Research Funding; Fresenius Biotech: Research Funding; Gamida Cell: Research Funding; Pluristem Ltd: Research Funding; Articulate Science.